FierceBiotechOriginal article
{"a":[{"_":"Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027","$":{"href":"/biotech/context-scraps-bispecific-program-extend-cash-runway-deeper-2027","hreflang":"en"}}]}
CT-95Negative
AI Analysis
Summary
Context Therapeutics has discontinued development of its bispecific T-cell engager CT-95 to preserve cash and extend its runway into 2027 while focusing on two priority clinical programs.
Outcome Details
Program discontinuation
Importance:4/10
Sentiment:
-0.60
program discontinuationcash runwaybispecific T-cell engagerclinical development
Related Companies
Read the original article
Published by FierceBiotech on August 6, 2026 5:56 AM